{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:07:05Z","timestamp":1750691225525},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"DOI":"10.7759\/cureus.46228","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T22:28:37Z","timestamp":1696026517000},"source":"Crossref","is-referenced-by-count":2,"title":["Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash"],"prefix":"10.7759","author":[{"given":"Ana Isabel","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cemlyn-Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Gamboa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman HG","year":"2019","unstructured":"Heijerman HG, McKone EF, Downey DG, et al.. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019, 394:1940-8. 10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton PG","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, et al.. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019, 381:1809-19. 10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"European Medicines Agency. Kaftrio 37,5 mg\/25 mg\/50 mg - Summary of product characteristics. Available. https.\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_pt.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.06.011","article-title":"A case of elexacaftor-tezacaftor-ivacaftor induced rash resolving without interruption of treatment","volume":"21","author":"Bhaskaran D","year":"2022","unstructured":"Bhaskaran D, Bateman K. A case of elexacaftor-tezacaftor-ivacaftor induced rash resolving without interruption of treatment. J Cyst Fibros. 2022, 21:1077-9. 10.1016\/j.jcf.2022.06.011","journal-title":"J Cyst Fibros"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-27.5.463","article-title":"Rechallenge of elexacaftor\/tezacaftor\/ivacaftor after skin rash in two pediatric patients","volume":"27","author":"Diseroad ER","year":"2022","unstructured":"Diseroad ER, Mogayzel PJ Jr, Pan A. Rechallenge of elexacaftor\/tezacaftor\/ivacaftor after skin rash in two pediatric patients. J Pediatr Pharmacol Ther. 2022, 27:463-6. 10.5863\/1551-6776-27.5.463","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-247042","article-title":"Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation","volume":"15","author":"Cheng A","year":"2022","unstructured":"Cheng A, Baker O, Hill U. Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation. BMJ Case Rep. 2022, 15:e247042. 10.1136\/bcr-2021-247042","journal-title":"BMJ Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.08.010","article-title":"Elexacaftor\/tezacaftor\/ivacaftor outpatient desensitization","volume":"128","author":"Balijepally R","year":"2022","unstructured":"Balijepally R, Kwong D, Zhu L, Camacho JV, Liu A. Elexacaftor\/tezacaftor\/ivacaftor outpatient desensitization. Ann Allergy Asthma Immunol. 2022, 128:104-5. 10.1016\/j.anai.2021.08.010","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/189135-triple-therapy-for-cystic-fibrosis-elexacaftor-tezacaftor-and-ivacaftor-desensitization-after-skin-rash","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:12Z","timestamp":1707509412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/189135-triple-therapy-for-cystic-fibrosis-elexacaftor-tezacaftor-and-ivacaftor-desensitization-after-skin-rash"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.46228","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}